A Phase 4 interventional study of Sacituzumab Govitecan-hiy in Metastatic Solid Tumors, sponsored by Gilead Sciences. Completed at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-30.
Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
This is a rollover study. Only participants who continue to receive clinical benefit from continuation of SG therapy and are tolerating therapy at the time of enrollment are eligible for this study. Participants enrolled may continue to receive SG at the dose that they were receiving in the Gilead parent study at the time of consenting to participate in this rollover study.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
All participants who previously received SG in the parent study (IMMU-132-01) will continue to receive the same dose of SG up to a maximum of 10 mg/kg, on Days 1 and 8 of 21-day cycle until progressive disease (PD), toxicity, withdrawal of consent, lost to follow-up or loss of clinical benefit, or sponsor termination of the study was documented and were followed for long-term safety up to maximum 3.9 years.
Drug: Sacituzumab Govitecan-hiy
All participants who previously received SG in the parent study (IMMU-132-05) will continue to receive the same dose of SG up to a maximum of 10 mg/kg, on Days 1 and 8 of 21-day cycle until PD, toxicity, withdrawal of consent, lost to follow-up or loss of clinical benefit, or sponsor termination of the study was documented and were followed for long-term safety up to maximum 3.9 years.
Drug: Sacituzumab Govitecan-hiy
All participants who previously received SG in the parent study (IMMU-132-15) will continue to receive the same dose of SG up to a maximum of 10 mg/kg, on Days 1 and 8 of 21-day cycle until PD, toxicity, withdrawal of consent, lost to follow-up or loss of clinical benefit, or sponsor termination of the study was documented and were followed for long-term safety up to maximum 3.9 years.
Drug: Sacituzumab Govitecan-hiy
Administered intravenously
Also known as: IMMU-132, Trodelvy™, GS-0132
Percentage of Participants Experiencing Any Adverse Events
An adverse event was defined as any untoward medical occurrence in a participant administered a medicinal product that does not necessarily have a causal relationship with this treatment.
Time frame: First dose date up to 30 days post last dose (Up to 3.9 years)
Percentage of Participants Experiencing Any Serious Adverse Events
A serious adverse event (SAE) was any untoward medical occurrence that, at any dose, was fatal (resulting in death), was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.
Time frame: First dose date up to 30 days post last dose (Up to 3.9 years)
Percentage of Participants Experiencing Any Grade and Grade 3 or 4 Laboratory Abnormalities
The percentage of participants experiencing any clinically significant laboratory abnormality was summarized.
Time frame: First dose date up to 30 days post last dose (Up to 3.9 years)
Participants were enrolled at study sites in the United States, Belgium and France.
| Milestone | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) |
|---|---|---|---|
| Started | 3 | 10 | 12 |
| Completed | 0 | 0 | 0 |
| Not completed | 3 | 10 | 12 |
| Withdrew: Adverse events resolution or stabilization | 3 | 4 | 0 |
| Withdrew: Death | 0 | 3 | 3 |
| Withdrew: Reason not specified | 0 | 2 | 4 |
| Withdrew: Withdrawal of consent | 0 | 0 | 5 |
| Withdrew: Site terminated by sponsor | 0 | 1 | 0 |
An adverse event was defined as any untoward medical occurrence in a participant administered a medicinal product that does not necessarily have a causal relationship with this treatment.
| percentage of participants | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) |
|---|---|---|---|
| Percentage of Participants Experiencing Any Adverse Events | 66.7 | 100.0 | 91.7 |
A serious adverse event (SAE) was any untoward medical occurrence that, at any dose, was fatal (resulting in death), was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.
| percentage of participants | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) |
|---|---|---|---|
| Percentage of Participants Experiencing Any Serious Adverse Events | 0 | 40.0 | 8.3 |
The percentage of participants experiencing any clinically significant laboratory abnormality was summarized.
| percentage of participants | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) |
|---|---|---|---|
| Any Grade 1 or Higher Laboratory Abnormalities | 100.0 | 88.9 | 81.8 |
| Grade 3 or 4 Laboratory Abnormalities | 33.3 | 44.4 | 72.7 |
Collected over Up to 3.9 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | 3/10 (30%) | 4/10 (40%) | 10/10 (100%) |
| Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) | 3/12 (25%) | 1/12 (8.3%) | 11/12 (91.7%) |
| Event | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) |
|---|---|---|---|
| ColitisGastrointestinal disorders | 0/3 | 1/10 | 0/12 |
| Chest painGeneral disorders | 0/3 | 1/10 | 0/12 |
| Covid-19Infections and infestations | 0/3 | 1/10 | 0/12 |
| Upper respiratory tract infectionInfections and infestations | 0/3 | 1/10 | 0/12 |
| LymphoedemaVascular disorders | 0/3 | 1/10 | 0/12 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/10 | 1/12 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/3 | 0/10 | 1/12 |
| HiccupsRespiratory, thoracic and mediastinal disorders | 0/3 | 0/10 | 1/12 |
| Event | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 2/3 | 4/10 | 4/12 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 6/10 | 2/12 |
| NauseaGastrointestinal disorders | 0/3 | 6/10 | 3/12 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 4/10 | 2/12 |
| Abdominal painGastrointestinal disorders | 0/3 | 4/10 | 3/12 |
| FatigueGeneral disorders | 0/3 | 4/10 | 2/12 |
| HeadacheNervous system disorders | 0/3 | 4/10 | 0/12 |
| Ventricular extrasystolesCardiac disorders | 1/3 | 0/10 | 0/12 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 1/3 | 0/10 | 0/12 |
| Urinary tract infectionInfections and infestations | 1/3 | 1/10 | 0/12 |
All Treated Participants Analysis Set included all participants who received ≥ 1 dose of study drug following enrollment into this rollover IMMU-132-14 study.
| Age, Categorical(Participants) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 8 | 10 | 18 |
| >=65 years | 3 | 2 | 2 | 7 |
| Age, Continuous(years) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) | Total |
|---|---|---|---|---|
| Mean | 71 ± 5.7 | 61 ± 10.4 | 49 ± 15.5 | 56 ± 14.7 |
| Sex: Female, Male(Participants) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) | Total |
|---|---|---|---|---|
| Female | 3 | 10 | 8 | 21 |
| Male | 0 | 0 | 4 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 3 | 3 |
| Not Hispanic or Latino | 3 | 10 | 8 | 21 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 2 |
| White | 3 | 7 | 9 | 19 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05) | Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15) | Total |
|---|---|---|---|---|
| Belgium | 0 | 2 | 0 | 2 |
| United States | 3 | 7 | 12 | 22 |
| France | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Oct 2024, 50 months.
Results were first posted in Sep 2025, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sacituzumab govitecan